Starpharma Signs Second Oncology Agreement With AstraZeneca

Starpharma与阿斯利康签署协议,推进开发肿瘤药物增强型版本

2019-06-04 12:09:00 BioSpace

本文共1629个字,阅读需5分钟

Starpharma has signed a Development and Option Agreement with AstraZeneca to progress the development of a Dendrimer Enhanced Product version of one of AstraZeneca’s major marketed oncology medicines. Following completion of agreed preclinical studies by Starpharma, AstraZeneca has the option to licence the DEP® oncology drug candidate for an option exercise fee of US$5M, plus industry standard development and commercialisation milestones and escalating royalties on sales. If AstraZeneca does not exercise the option to license the drug candidate, Starpharma has the option to license the rights to develop and commercialise the drug candidate itself or through a sub-licensee with milestones and royalties paid to AstraZeneca upon commercialisation of the product. This second oncology agreement follows an existing multiproduct licence for use of Starpharma’s DEP® drug delivery platform in the development and commercialisation of several AstraZeneca oncology drug candidates, including AZD0466. Starpharma Holdings Ltd today announced a Development and Option Agreement with AstraZeneca to progress the development of a Dendrimer Enhanced Product (DEP®) version of an undisclosed AstraZeneca major marketed oncology medicine. This is the second DEP® commercial agreement Starpharma has signed with AstraZeneca, the first agreement being a multiproduct licence which covers novel oncology drug candidates such as AZD0466 (a Bcl2/xL inhibitor). The agreement was signed during the 2019 ASCO (American Society of Clinical Oncology) meeting in Chicago. ASCO attracts more than 40,000 cancer doctors, scientists, investors, pharmaceutical and life science executives. Under this agreement, Starpharma will conduct preclinical testing of the DEP® version of the AstraZeneca oncology product. At any time from the signing of this agreement and for a defined period after the completion of this testing, AstraZeneca may exercise its option and licence the DEP® drug candidate for clinical and commercial development. If AstraZeneca exercises the option, an option exercise fee of US$5 million is payable to Starpharma, as well as industry standard development and commercialisation milestones and escalating royalties on sales. Further details regarding the major oncology medicine involved, drug candidates, and terms of the agreement remain confidential at this time for competitive reasons. In the event AstraZeneca does not exercise its option to licence the DEP® drug candidate within the defined period, Starpharma has the option to license the rights to develop and commercialise this DEP® drug either itself or through a sub-licensee with milestones and royalties paid to AstraZeneca upon commercialisation of the resultant DEP® product. Dr Jackie Fairley, Starpharma Chief Executive Officer, said: “We are delighted to sign a new commercial DEP® agreement at ASCO with our long-standing partner, AstraZeneca. This agreement follows a successful research program under which we identified a promising DEP® candidate with a number of potential benefits. This agreement represents the culmination of that work and this DEP® product has the potential to provide significantly enhanced patient benefit. Unlike our first DEP® agreement with AstraZeneca, which applies DEP® to novel oncology drug candidates, this agreement is for an existing major AstraZeneca oncology medicine and provides further validation of the value of the DEP® platform and its broad application to both new chemical entities and existing products.” Susan Galbraith, Senior Vice President, R&D Early Oncology, AstraZeneca, said: "Building on our long-standing and successful working relationship with Starpharma, this agreement will enable us to further evaluate the potential of the DEP® technology with the aim of improving treatment outcomes for patients.” Starpharma’s DEP® platform remains available for further partnerships. Licences are typically product specific and structured to allow for multiple partnered-DEP® programs to run in parallel.
Starpharma 已与 AstraZeneca 签署《开发和选择协议》,以推进阿斯利康(AstraZeneca)主要上市肿瘤药物之一的 Dendrimer 增强型产品版本的开发。 在 Starpharma 完成商定的临床前研究后,阿斯利康(AstraZeneca)有权向 DEP ®肿瘤学候选药物授予500万美元的期权执行费,外加行业标准开发和商业化里程碑以及不断增加的销售版税。 如果 AstraZeneca 不行使许可候选药物的选择权,则 Starpharma 有权许可该候选药物本身开发和商业化的权利,或通过分许可人在产品商业化时向阿斯利康(AstraZeneca)支付里程碑和特许权使用费。 第二个肿瘤学协议是在 Starpharma 的 DEP ®药物交付平台开发并商业化包括 AZD0466在内的几个阿斯利康(AstraZeneca)肿瘤药物候选者的现有多产品许可之后达成的。 Starpharma Holdings Ltd 今天宣布与 AstraZeneca 签订一项开发和选择协议,以推进 Dendrimer 增强型产品( DEP ®)的开发,该产品是一种未披露的阿斯利康(AstraZeneca)主要上市肿瘤药物。这是 Starpharma 与阿斯利康(AstraZeneca)签署的第二个 DEP ®商业协议,第一个协议是多产品许可,涵盖 AZD0466(一种 Bcl2/ xL 抑制剂)等新型肿瘤药物候选。 该协议是在2019年美国临床肿瘤学会( AmericanSocietyofClinicalOncology )芝加哥会议上签署的。ASCO 吸引了40,000多名癌症医生、科学家、投资者、医药和生命科学高管。 根据本协议, Starpharma 将对阿斯利康(AstraZeneca)肿瘤产品的 DEP ®版本进行临床前测试。在本协议签署之日起的任何时间以及在本试验完成后的规定期限内,阿斯利康(AstraZeneca)可行使其选择权,并许可 DEP ®药物候选人进行临床和商业开发。如果阿斯利康(AstraZeneca)行使选择权,则应向 Starpharma 支付500万美元的期权执行费,以及行业标准开发和商业化里程碑以及不断增加的销售特许权使用费。有关所涉及的主要肿瘤药物、候选药物、协议条款的进一步详情,目前因竞争原因仍保密。 如果 AstraZeneca 没有在规定期限内行使其许可 DEP ®候选药物的选择权,则 Starpharma 有权自行或通过分许可人许可开发和商业化该 DEP ®药物的权利,并在相关 DEP ®产品商业化后向阿斯利康(AstraZeneca)支付里程碑和特许权使用费。 Starpharma 首席执行官杰基•费尔利( Jackie Fairley )博士表示:“我们很高兴与我们的长期合作伙伴阿斯利康( AstraZeneca )在 ASCO 签署新的商业 DEP ®协议。该协议遵循一个成功的研究计划,根据该计划,我们确定了一个有前途的 DEP ®候选人,并具有许多潜在的优势。该协议代表了该工作的最终成果,该 DEP ®产品有可能提供显著增强的患者利益。与我们与 AstraZeneca 签订的第一份 DEP ®协议不同,该协议将 DEP ®应用于新的肿瘤药物候选者,该协议针对现有的主要阿斯利康(AstraZeneca)肿瘤药物,并进一步验证 DEP ®平台的价值及其对新化学实体和现有产品的广泛应用。” 阿斯利康(AstraZeneca)研发早期肿瘤学高级副总裁 Susan Galbraith 表示:“基于我们与 Starpharma 的长期成功合作关系,该协议将使我们能够进一步评估 DEP ®技术的潜力,以改善患者的治疗结果。” Starpharma 的 DEP ®平台仍可用于进一步合作。许可证通常是针对特定产品和结构化的,以允许多个合作伙伴-DEP ®程序并行运行。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文